The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022

The 2022 Immunotherapy Bridge congress (November 30–December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and considered whether adoptive cell therapy (ACT) has...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Brentjens, Renier, Khleif, Samir N., Odunsi, Kunle, Rezvani, Katayoun, Ruella, Marco, Sullivan, Ryan J., Fox, Bernard A., Puzanov, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122806/
https://www.ncbi.nlm.nih.gov/pubmed/37087493
http://dx.doi.org/10.1186/s12967-023-04117-3
_version_ 1785029562975911936
author Ascierto, Paolo A.
Brentjens, Renier
Khleif, Samir N.
Odunsi, Kunle
Rezvani, Katayoun
Ruella, Marco
Sullivan, Ryan J.
Fox, Bernard A.
Puzanov, Igor
author_facet Ascierto, Paolo A.
Brentjens, Renier
Khleif, Samir N.
Odunsi, Kunle
Rezvani, Katayoun
Ruella, Marco
Sullivan, Ryan J.
Fox, Bernard A.
Puzanov, Igor
author_sort Ascierto, Paolo A.
collection PubMed
description The 2022 Immunotherapy Bridge congress (November 30–December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and considered whether adoptive cell therapy (ACT) has a role in the treatment of solid tumors, the use of peripheral/blood biomarkers versus tumor microenvironment biomarkers for cancer immunotherapy and the role of chimeric antigen receptor T cell versus natural killer cell therapy. As is the tradition in the Immunotherapy Bridge Great Debates, speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect their own personal views. Audiences voted in favour of either side of the topic both before and after each debate.
format Online
Article
Text
id pubmed-10122806
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101228062023-04-24 The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022 Ascierto, Paolo A. Brentjens, Renier Khleif, Samir N. Odunsi, Kunle Rezvani, Katayoun Ruella, Marco Sullivan, Ryan J. Fox, Bernard A. Puzanov, Igor J Transl Med Meeting Report The 2022 Immunotherapy Bridge congress (November 30–December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and considered whether adoptive cell therapy (ACT) has a role in the treatment of solid tumors, the use of peripheral/blood biomarkers versus tumor microenvironment biomarkers for cancer immunotherapy and the role of chimeric antigen receptor T cell versus natural killer cell therapy. As is the tradition in the Immunotherapy Bridge Great Debates, speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect their own personal views. Audiences voted in favour of either side of the topic both before and after each debate. BioMed Central 2023-04-22 /pmc/articles/PMC10122806/ /pubmed/37087493 http://dx.doi.org/10.1186/s12967-023-04117-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Meeting Report
Ascierto, Paolo A.
Brentjens, Renier
Khleif, Samir N.
Odunsi, Kunle
Rezvani, Katayoun
Ruella, Marco
Sullivan, Ryan J.
Fox, Bernard A.
Puzanov, Igor
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
title The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
title_full The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
title_fullStr The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
title_full_unstemmed The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
title_short The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
title_sort “great debate” at immunotherapy bridge 2022, naples, november 30th–december 1st, 2022
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122806/
https://www.ncbi.nlm.nih.gov/pubmed/37087493
http://dx.doi.org/10.1186/s12967-023-04117-3
work_keys_str_mv AT asciertopaoloa thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT brentjensrenier thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT khleifsamirn thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT odunsikunle thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT rezvanikatayoun thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT ruellamarco thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT sullivanryanj thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT foxbernarda thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT puzanovigor thegreatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT asciertopaoloa greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT brentjensrenier greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT khleifsamirn greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT odunsikunle greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT rezvanikatayoun greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT ruellamarco greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT sullivanryanj greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT foxbernarda greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022
AT puzanovigor greatdebateatimmunotherapybridge2022naplesnovember30thdecember1st2022

Ejemplares similares